Phase Forward to Host Eighth Annual International Users Conference, November 3-5, Boston
November 02 2009 - 9:00AM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, will host
its eighth annual International Users Conference (IUC) this week.
Under the theme “Powering More Possibilities,” the conference will
be held at the Sheraton Boston Hotel in Boston.
Former CEO of Novazyme Pharmaceuticals, Inc. and president and
CEO of Amicus Therapeutics, John F. Crowley will deliver the
opening keynote address during which he will discuss his personal
journey to find a cure for Pompe disease and his experience in
bringing new therapies to market. After his two youngest children
were diagnosed with Pompe disease, he decided to leave his post at
Bristol-Myers Squibb to become Novazyme’s CEO, where he ultimately
helped the company develop a therapy for Pompe disease. In 2001
Novazyme merged into Genzyme Corporation.
An additional keynote will be delivered by P. K. Tandon, Ph.D.,
senior vice president, global biomedical data sciences and
informatics at Genzyme Corporation. Dr. Tandon joined Genzyme in
1997 and is responsible for leading a global group encompassing
biostatistics, data management, statistical programming, electronic
data submissions and data capture, information systems and medical
writing.
A third keynote will be given by Charles Cooper, M.D., medical
officer of the Office of Translational Sciences Center for Drug
Evaluation and Research (CDER) at FDA. In his presentation, Dr.
Cooper will discuss the challenges and future directions of
computational science at CDER.
“The annual conference offers an opportunity for peer-to-peer
networking and learning,” said Bob Weiler, chairman and CEO, Phase
Forward. “It is within this forum that we can highlight the vision
and continued success of our customers and partners, and discuss
the ways in which we can continue to deliver the types of products
and services they need to focus on the critical work of bringing
new and improved therapies to market.”
The conference will also offer:
- Four pre-conference workshops
developed to offer customers insights into combining Phase
Forward’s IRT and InForm™ systems, efficiently transforming
clinical data collected with InForm into SDTM format, as well as an
update on the capabilities of the company’s Empirica™ Signal and
Empirica™ Trace products.
- More than 30 customer-driven
sessions with three concurrent tracks, including a dedicated track
focused on safety and strategic pharmacovigilance. Topics include
the implementation, integration and optimization of solutions in
the areas of study design and standards, EDC, IRT, ePRO, data
integration, and clinical data repositories to support integrated
data analysis.
- A partner exhibit area featuring
sponsors AG Mednet, Akamai Technologies, Sentrx and the Uppsala
Monitoring Centre.
- A demo room highlighting Phase
Forward’s Integrated Clinical Research Suite.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jul 2023 to Jul 2024